SIU-SOM |About SIU-SOM|Directories|News & Information|SIU-Carbondale|Search
Otolaryngology banner
Fellowship|Residency|Research Interests|The Cancer Institute|The Breast Center| The Trauma Center | The Cutting Edge

Leonard P. Rybak, M.D., Ph.D.
Professor
Department of Surgery
SIU School of Medicine
Division of Otolaryngology - Head and Neck Surgery

 

 

P.O. Box 19649
Springfield, IL 62794-9649
Business Phone 217-545-6099
Business Fax 217-545-7781

Brief Bio

Research Interests/Areas of Expertise:

  • Growth of cochlear hair cells derived from Immortomouse (HEI-OC1, OC-k3 cells) in culture
  • Ototoxicity of cisplatin, carboplatin and loop diuretics and chemoprevention
  • Mechanisms controlling free radical production within the cochlea
  • Auditory development and ototoxicity during development
  • Scanning and transmission electron microscopy of the cochlea
  • Mechanisms of noise-induced hearing loss and pharmacological prevention
  • Cell death and cell replacement pathways in the cochlea

 

Dr. Leonard P. Rybak, is a professor and ear, nose and throat specialist whose general otolaryngology practice focuses on sinus disease and obstructive sleep apnea.
Dr. Rybak received his medical degree from the Medical College of Wisconsin-Milwaukee and completed his internship at Hennepin County Medical Center in Minneapolis. He completed a residency in otolaryngology and also obtained a Ph.D. at the University of Minnesota-Minneapolis. He served as an Assistant Professor of Otolaryngology at the University of Minnesota prior to coming to the SIU School of Medicine.
Dr. Rybak's professional affiliations include the American College of Surgeons, and the American Academy of Otolaryngology -- Head and Neck Surgery. Locally, he is a member of the Sangamon County Medical Society and of various committees at St. John’s Hospital and the SIU School of Medicine. He serves as president of the Sangamon County Chapter of the Society for Neuroscience.
As a clinician and surgeon, Dr. Rybak's special interests include general otolaryngology, sleep apnea, and head and neck surgery. Known both nationally and internationally for his research in the field of otolaryngology, Dr. Rybak has published and presented numerous articles and chapters dealing with various aspects of ear, nose and throat diseases. He is certified by the American Board of Otolaryngology.
For more information or to schedule an appointment with Dr. Rybak, please call 217-545-6099.

Education

St. Louis College of Pharmacy B.S 1969 -- Pharmacy
Medical College of Wisconsin M.D. 1973 -- Medicine
University of Minnesota Ph.D. 1979 -- Pharmacology/ Otolaryngology

Honors and Awards

  • Illinois State Scholarship 1964
  • American Foundation for Pharmaceutical Education Scholarships 1964,1969
  • President's Award for Highest Grade Point Average 1967-1969
  • Rho Chi Pharmaceutical Honor Society 1968
  • B.S. Summa Cum Laude 1969
  • Alpha Omega Alpha Medical Honor Society 1972
  • William Douglas Brooker Award in Pharmacology 1973
  • Teacher Investigator Development Award from NIH (NINCDS) 1979,1982
  • Physician's Recognition Award, American Medical Association 1981
  • Honor Award, American Academy of Otolaryngology, Head and Neck Surgery 1984
  • Selected for United States Pharmacopeia Committee of Revision 1985-1990
  • Honorable Mention (basic science) for Triological Thesis 1985
  • Appointed to NIH Study Section Hearing Research 1988-1992
  • Jacob Javits Neuroscience Investigator Award, NIH 1988-1995
  • Editorial Review Board, Laryngoscope 1989-
  • Selected for United States Pharmacopeia Committee of Revision
  • Otorhinolaryngology (second term) 1990-1995
  • Guest Editor for an issue of The Otolaryngologic Clinics of North America,
  • W. B. Saunders Co., publisher. 1993
  • Associate Editor, General Otolaryngology, Otolaryngology--Head andNeck Surgery. 1992-1995
  • Favorite Son Award, Southern Illinois Medical Association 1992
  • Board Member, Sangamon County Chapter, American Cancer Society 1992-1998
  • Secretary-Treasurer, Association for Research in Otolaryngology 1993-1996
  • Distinguished Alumni Award, Department of Otolaryngology,
  • University of Minnesota Medical School 1993
  • Elected to Membership Collegium ORLAS 1994
  • President, Sangamon County Chapter, American Cancer Society 1995-1996
  • President-Elect, Association for Research in Otolaryngology 1996-1997
  • President, Association for Research in Otolaryngology 1997-1998
  • President, Sangamon Chapter, Society for Neuroscience 2000-2001
  • Secretary/Treasurer, Christian Society of Otolaryngologists, Head and Neck Surgeons 2000 –2004
  • Distinguished Service Award, American Academy of Otolaryngology-Head and Neck Surgery 2002
  • President, Illinois Catholic Medical Association 2003-2004
  • Best Doctors in America (otolaryngology) 2003-2004
  • Guest of Honor, International Tinnitus Forum, New York Marriott Marquis Hotel, New York , New York September 18, 2004
  • Award for Excellence in Teaching of Residents, Department of Surgery, SIU School of Medicine December 2, 2004

Professional Experience

  • St. Louis College of Pharmacy, St. Louis, MO (B.S.) 1964-1969
    Teaching and laboratory assistant in physiology, pharmacology and toxicology, St. Louis College of Pharmacy, St. Louis, MO. 1966-1969
  • Staff Pharmacist, St. Luke's Hospital, Milwaukee, WI 1971-1973
  • Medical College of Wisconsin, Milwaukee, WI (M.D.) 1969-1973
  • Summer fellowship in preventive medicine for "Lead Poisoning June-Sept 1971 Screening", Medical College of Wisconsin, Milwaukee, WI
  • Rotating internship, Hennepin County Medical Center, Minneapolis , MN 1973-1974
  • Resident in otolaryngology, University of Minnesota Minneapolis , MN 1975-1979
  • Ph.D. candidate, University of Minnesota, Minneapolis, MN (Otolaryngology - major; Pharmacology - minor) Degree granted 8-17-79 1974-1979
  • Assistant Professor, Department of Otolaryngology, University of Minnesota , Minneapolis, MN 1979-1981
  • Attending staff, Department of Otolaryngology, Hennepin County Medical Center, Minneapolis, MN 1979-1981
  • Assistant Professor, Department of Surgery-Division of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL (cross appointment in pharmacology) 1981-1983
  • Associate Professor, Department of Surgery-Division of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL (cross appointment in pharmacology) 1983-1989
  • Professor, Department of Surgery-Division of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL (cross appointment in pharmacology) 1989-present
  • Temporary Staff Appointment, St. Jude's Hospital, St. Lucia, 07/13/92- West Indies (Medical Volunteer) 08/15/92

Selected Recent Bibliography

1. Rybak LP, Ravi R and Somani S. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fund Appl Toxicol 26:293-300, 1995.
PHS 398 (Rev. 4/98)
2. Somani SM, Ravi R and Rybak LP. Diethyldithiocarbamate protection against cisplatin nephrotoxicity: Antioxidant system. Drug Chem Toxicol 18:151-170, 1995.
3. Ramkumar V, Nie Z, Rybak LP and Maggirwar S. Adenosine, antioxidant enzymes and cytoprotection. Trends in Pharmacol Sciences 16:283-285, 1995.
4. Kanno H, Yamanobe S and Rybak LP. The ototoxicity of deferoxamine mesylate. Am J Otolaryngol 16:148-152, 1995.
5. Kanno H, Yamanobe S, Ohtani I and Rybak LP. Deferoxamine mesylate associated sensorineural hearing loss. Practica Otologia (Kyoto) 83:170-175, 1995.
6. Ma YL, Gerhardt KJ, Curtis GM, Rybak LP, Whitworth C and Rarey KE. Combined effects of adrenalectomy and noise exposure on compound action potentials, endocochlear potentials and potassium concentration. Hear Res 91:79-86, 1995.
7. Ma YL, Gerhardt KJ, Rybak LP, Curtis LM and Rarey KE. In situ real-time sequential potentiometric determination of potassium concentrations from four cochlear regions in noise-exposed rats. Eur Arch Oto-Rhino-Laryngol 253:201-204, 1996.
8. Ma YL, Rarey KE, Gerhardt KJ, Curtis LM and Rybak LP. Electrochemical potentials and potassium concentration profiles recorded from perilymph, endolymph and associated inner ear tissues in adrenalectomized rats. Hear Res 96:151-156, 1996.
9. Husain K, Morris C, Whitworth C, Trammel GL, Rybak LP and Somani SM. 4-methylthiobenzoic acid protection against cisplatin nephrotoxicity: Antioxidant system. Fund Appl Toxicology 32:278-284, 1996.
10. Somani SM and Rybak LP. Comparative effects of exercise training on transcription of antioxidant enzyme and the activity in old rat heart. Indian J Physiol Pharmacol 40:205-212, 1996.
11. Campbell KCM, Naritoku D, Evans MS, Hughes LF and Rybak LP. Is valproic acid ototoxic? American Journal of Audiology 5:7-10, 1996
12. Rybak LP. Ototoxicity. Current Opinion in Otolaryngology & Head and Neck Surgery, 4:302-307, 1996.
13. Campbell KCM, Rybak LP. Sensorineural hearing loss and dyslipidemia. American Journal of Audiology 5:11-14, 1996.
14. Campbell KCM, Rybak LP, Meech RP and Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102:90-98, 1996.
15. Ravi R, Krall A, Rybak LP, Struble RG. Olfactory mucosal lesions following subcutaneous diethyldithiocarbamate (DDTC). Neurotoxicology 18:123-128,1997
16. Kopke RD, Lui W, Gabaizadeh R, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben R, Rybak LP and Van de Water TR. The use of organotypic cultures of Corti's organ to study protective effects of antioxidant molecules on cisplatin induced damage of auditory hair cells. Am J. Otol, 18:559-571,1997.
17. Ford MS, Maggirwar SB, Rybak LP, Whitworth C, Ramkumar V. Expression and function of adenosine receptors in the chinchilla cochlea. Hear Res 105:130-140, 1997.
18. Ford MS, Nie Z, Whitworth C, Rybak LP, Ramkumar V. Up-regulation of adenosine receptors in the cochlea by cisplatin. Hear Res 111:143-152, 1997.
19. Rybak LP, Husain K, Evenson L, Morris C, Whitworth C and Somani S. Protection by 4-methylthiobenzoc acid against cisplatin-induced ototoxicity: Antioxidant system. Pharmacol Toxicol 81:173-179,1997.
20. Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP and Somani SM. Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system. Mole Cell Biochem 178:127-133,1998.
21. Janning MH, Whitworth CA and Rybak LP. An experimental model of cisplatin ototoxicity in chichillas. Otolaryngol Head and Neck Surg 119:574-580, 1998.
22. Nie Z, Mei Y, Ford MS, Rybak LP, Marcuzzi A, Ren H, Stiles GL and Ramkumar V. Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B. Mol Pharmacol 53:663-669,1998.
23. Mills CD, Whitworth C, Rybak LP and Henky CM. Quantification of furosermide from serum and tissues using high-performance liquid chromatography. J Chromatogr B 701:65-70,1997
24. Whitworth CA, Hudson TE and Rybak LP. The Effect of Combined Administraton of Cadmium and Furosemide of Auditory Function in the Rat. Hearing Research 129: 61-70, 1999
25. Rybak LP, Husain K, Whitworth C and Somani SM. Dose Dependent Protection by Lipoic Acid against Cisplatin-Induced Ototoxicity in Rats: Antioxidant Defense System. Toxicol Sci. 47:195-202, 1999.
26. Kamimura T, Whitworth CA, Rybak LP. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hearing Research 131:117-127, 1999
27. Rybak LP. Ototoxicity and Antineoplastic Drugs. Current Opinon in Otolaryngology and Head and Neck Surgery 7:239-243, 1999
28. Rybak LP, Husain K, Morris C, Whitworth CA and Somani S. Effects of protective agents against cisplatin ototoxicity. Am J Otol. 21:513-520, 2000
29. Rybak LP, Whitworth CA and Somani S. Application of Antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 109:1740-1744, 1999.
30. Campbell KC, Meech RP, Rybak LP and Hughes LF. D-methionine protects against cisplatin damage to the stria vascularis. Hearing Research (in press).
31. Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M and Rybak LP. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol & Toxicol, 86:234-241, 2000.
32. Whitworth, C.A., Rybak, L.P., Kemp, R. and Spence, S.: Pharmacological antagonism of the slow-rectifying potassium channel (IKS) has no effect on the cochlear structure and function in vivo. Pharmacol & Toxicol 88; 45-50, 2001.
33. Somani, S.M., Husain, K., Jagannathan, R. and Rybak, L.P.: Amelioration of cisplatin-induced oto and nephro toxicity by protective agents. Annals of Neuro: 8:101-113, 2001
34. Husain, K., Scott, R.B., Whitworth, C., Somani, S.M. and Rybak, L.P.: Dose-response of carboplatin-induced hearing loss in rats: Antioxidant system. Hear Res 151:71-78, 2001.
35. Armour, G., Mhaskar, Y., Rybak, L.P. and Dunaway, G.: Alteration of 6-phosphofructo-1-kinase subunits during maturation of the rat cochlear cells. Hear Res 151:149-156, 2001.
36. Husain, K., Whitworth, C., Somani, S. and Rybak, L.P.: Carboplatin-induced oxidative stress in rat cochlea. Hear Res 158:14-22, 2001.
37. Korver, K., Rybak, L.P., Whitwort C. and Campbell, K.C.M.: Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 126:683-689, 2002
38. Bhat, S.G., Mishra, S., Mei, Yun, Nie, Z., Whitworth, C.A., Rybak, L.P. and Ramkumar, V.: Cisplatin up-regulates the adenoside A1 receptor in the rat kidney. Euro Jour of Pharmacol 442: 251-264, 2002.
39. Husain, K., Jagannathan, R., Zeshan, H., Trammel, G.L., Rybak, L.P., Hazelrigg, S.R. and Somani, S.M.: Dose Response of Carboplatin-induced Nephrotoxidity in rats. Phamacol & Toxicol 91:83-89, 2002.
40. Donnersberger, D.R., Campbell, K.C.M., Meech, R.P., Rybak, L.P., Hughes, L.F. and Nanavati, P.J.: A model for acute marked radiation-induced hearing loss. Journal of Burns (journalofburns.com) 1-8, 2002.
41. Dunaway, G., Mhaskar, Y., Armour, G., Whitworth, C. and Rybak, L.P.: Migration of cochlear lateral wall cells. Hear Res 177:1-11, 2003.
42. Tanaka, F., Whitworth, C. and Rybak, L.P.: Influence of pH on the ototoxicity of cisplatin: A round window application study. Hear Res 177:21-31, 2003.
43. E.M., Cass, S.P., Rybak, L.P. and Nedzelski, J.: Chemical treatment of the labyrinth. In: D.E. Brackman, C. Shelton, and M. Arriaga (eds) Otologic Surgery, second edition, Saunders, Philadelphia:2001, pp.413-421.
44. Rybak, L.P. and Touliatos, J.: Ototoxicity, In: J.B. Snow, Jr. and J.J. Ballenger (eds), Ballenger's Otorhinolaryngology, Head and neck Surgery, Sixteenth Edition, B.C. Decker, Hamilton, Ontario, Canada, pp. 374-380, 2003
45. Manolidis, S., Friedman, R., Hannley, M., Roland, P.S., Matz, G., Rybak. L, Stewart, M.G., Weber, P. and Owens, F.: Comparative efficacy of aminoglycoside versus fluoroquinolone topical antibiotic drops. Otolaryngol Head Neck Surg 2004; 130:S83-S88
46. Weber, P., Roland, P.S., Hannley, M., Friedman, R., Manolidis, S., Matz, G., Owens, F., Rybak. L and Stewart, M.G.: The development of antibiotic resistant organisms with the use of ototopical medications. Otolaryngol Head Neck Surg; 30:S89-S94

Research Support

Title: Endogenous Modulation of Cochlear Injury

PI: Leonard P. Rybak, M.D., Ph.D. (Vickram Ramkumar, Ph.D., Co-Investigator)

Agency: NIH/National Institute on Deafness and Other Communicative Disorders

Award period: 04/01/04-03/31/07

Specific aims: The purpose of this grant is to study the up-regulation of adenosine receptors in the cochlea following cisplatin administration. The specific aims are: 1) to characterize and localize the adenosine receptor subtypes in the cochlea; 2) to investigate the mechanism of up-regulation of AR in the cochlea induced by cisplatin; 3) to investigate the protective effect of the adenosine receptor agonist, R-PIA; 4) to test the hypothesis that preconditioning stress by noise exposure causes an up-regulation of adenosine receptors in the cochlea.

Grants

  • Perilymph Osmolality Response to Osmotic Diuretics (urea, glycerol, mannitol), Investigator, NIH Grant #NS 12125-01, July 1, 1975-December 31, 1979.
  • Quantitative Study of Ototoxic Drugs and Inner Ear Function, Investigator, NIH Grant #NS 12125-01, July 1, 1975-December 31, 1979.
  • PHS National Research Service Award #5 T32 NS 007084-82 0021, Principal Investigator, July 1, 1978-June 30, 1979.
  • Effects of Ototoxic Drugs on Cochlear Structure and Function, Principal Investigator, Teacher Investigator Development Award from NIH-NINCDS #K 07 NS 00492-2, December 1, 1979-November 30, 1984.
  • Ototoxicity of Otic Drops and Antiseptics, Investigator, NIH Grant #NS 14538, 1979-1981.
  • Ototoxicity of Furosemide, Central Research Committee Grant, SIU School of Medicine, Principal Investigator, 1981-1982.
  • Effects of Putative Amino Acid Neurotransmitters in an Invitro Cochlear Nucleus Model, Central Research Committee Grant, SIU School of Medicine, Co-investigator, July 1, 1981-June 30, 1982.
  • Coding in Auditory Neurons: Effects of Amino Acids, Co-investigator, NIH (NINCDS) #NS 15640, January 1, 1982-December 31, 1986.
  • Ototoxicity of Furosemide: Electrophysiologic and Pharmacokinetic correlations, Principal Investigator, Deafness Research Foundation, $10,000/yr., January 1, 1982-December 31, 1984.
  • Effect of Furosemide on Cochlear Function, NIH Teacher Investigator Award, Principal Investigator, April 1, 1982-March 31, 1985, grant #KO7NS00705 $40,028 per year.
  • Neurotransmitters of the Superior Olivary Complex: An Iontophoretic Study, Co-investigator, Deafness Research Foundation, January 1, 1983-December 31, 1983.
  • Ototoxicity in the Developing Kitten. Deafness Research Foundation, Principal Investigator, $10,000/yr. January 1, 1985-December 31, 1985. $12,500 January 1, 1986-December 31, 1987.
  • Development of an Animal Model for Otosclerosis. Central Research Committee Grant. Principal Investigator, $5,000 1981-1984.
  • Neuropharmacological Aspects of Auditory System Development. Deafness Research Foundation. Co-investigator, $10,000, 1984-1985.
  • Inferior Colliculus Neurotransmission: Micro-application studies in normal and audiogenic seizure prone animals. Deafness Research Foundation. Co-investigator, $10,000, 1984-1985.
  • Ototoxicity of Furosemide in the Neonate. Deafness Research Foundation. Co-investigator, $10,000, 1984-1985.
  • Effects of Organic Acids on Loop Diuretic Ototoxicity. National Institutes of Health. (NINCDS) NIH#R01 NS22530-01. Principal Investigator, July 1, 1985-June 30, 1988.
  • The Pharmacology of Convulsant Drugs. National Institutes of Health. (NINCDS) NIH #NS13849, $161,995. Co-investigator, June 31, 1986-July 31, 1989.
  • Coding in Auditory Neurons: Effects of Amino Acids. National Institutes of Health. (NINCDS) NIH#NS15640. $281,699. Co-investigator, July 1986-June, 1990.
  • Effects of Organic Acids on Loop Diuretic Ototoxicity. National Institutes of Health. (NINCDS) NIH#RO1 NS 22530-01-10. $700,000. Principal Investigator, 1988-1995. Javits Neuroscience Investigator Award. *
  • Endogenous Modulation of Oto-and Nephrotoxicity. Subcontract with Dartmouth Medical School. $400,000. #1 R01 GM 38218-01A1. Co-investigator, December 1, 1987-November 30, 1992.
  • A New Model for Metabolic Hearing Loss. Deafness Research Foundation. $15,000. January 1, 1988-December 31, 1990. Investigator.
  • Development of the Stria Vascularis: Structure-Function Studies. Central Research Committee, SIU School of Medicine, $4,750. Principal Investigator, July 1, 1991-June 30, 1992.
  • Age Related Effect of Exercise on Cardiac Mitochondrial and Cystosolic GSH in Rat. American Heart Association, $40,000. Co-investigator. July 1, 1991-June 30, 1993.
  • Coding in Auditory Neurons: Role of Excitant Amino Acids. Co-investigator. (Donald Caspary, Ph.D., Principal Investigator) July 1, 1990 - June 30, 1994, $811,030.
  • Microhomeostasis of the Cochlear Duct. Co-investigator. (Kyle Rarey, Ph.D., Principal Investigator). Subcontract with University of Florida. April 1, 1992 - March 31, 1994. $182,136.
  • The Effects of Hyperbaric Oxygen on Noise-Induced Hearing Loss. Co-investigator. (Martin H. Janning, M.D., Principal Investigator) 1993 Hyperbaric Research & Development Grant. January 1, 1993 - December 31, 1993. $2,700.00.
  • Flow Cytometer with Cell Sorting Capability. Co-investigator. (Ram P. Tewari, Ph.D., Principal Investigator) National Institutes of Health (Division of Research Resources) August 21,1992 - August 20, 1993. $275,000.
  • Role of Adenosine in Rat Cochlea. Co-investigator. (Vickram Ramkumar, Ph.D., Principal Investigator) Deafness Research Foundation, 1/1/94 - 12/31/95. $15,000.
  • Endogenous Modulation of Ototoxicity of Cisplatin. Principal Investigator. National Institutes of Health. July 1, 1994 - June 30, 1998, $849,319.
  • Effect of Development on Loop Diuretic Ototoxicity. Principal Investigator. National Institutes of Health. July 1, 1995 - June 30, 2000. $763,619
  • Effect of Cisplatin/Epinephrine Injectable Gel (Product MPI 5010) When Administered Intratumorally for Achievement of Treatment Goals in Recurrent or Refractory Squamous Cell Carcinoma of the Head and Neck. Principal Investigator. Matrix Pharmaceutical, Inc. February 2, 1996 - February 1, 1997. $101,490.
  • Exploratory Oral Ototoxicity Study in Male Rats. Principal Investigator. Merck Research Laboratories. September 1, 1996 - March 31, 1997. $48,928.
  • Biological mechanisms of noise-induced hearing loss, Co-Investigator. National Institutes of Health, National Institute on Deafness and Other Communicative Disorders August 1, 2001 – July 31, 2003, $200,000
  • Endogenous Modulation of Cochlear Injury. Principal Investigator, National Institutes of Health, National Institute on Deafness and Other Communicative Disorders ( R01 DC 02396). April 1, 1999-March 31, 2004, $878,673.
  • Endogenous Modulation of Cochlear Injury. Principal Investigator, National Institutes of Health, National Institute on Deafness and Other Communicative Disorders (R01 DC 02396). April 1, 2004-March 31, 2007, $ 675,000. *
  • Restoration of Cochlear Function by Cell Transplantation, Principal Investigator, American Otological Society Research Fund, July 1, 2004-June 30, 2005, $40,000.*
  • Nuclear Factor Kappa B and Renal A1 Adenosine Receptor, Co-Investigator, Principal Investigator Vickram Ramkumar, Excellence in Academic Medicine Award, SIU School of Medicine, January 1, 2005-December 31, 2005, $50,000*
  • Nuclear Factor Kappa B and Renal A1 Adenosine Receptor, Co-investigator, Principal Investigator Vickram Ramkumar, NIH, submitted October 1, 2004, funding requested for 7/1/05 to 6/30/10, $1,000,000 direct costs requested.

 

* Indicates currently active grant.


 
email link